Announcements Trials
Browse Landscape

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Plasma cell 1Other 1

Conditions

Cardiotoxicity 6Lymphoma, Non-Hodgkin 4Lymphoma 3Breast Neoplasms 3Prostatic Neoplasms 2Multiple Myeloma 2Leukemia 2Cardiovascular Diseases 2Small Cell Lung Carcinoma 1Obesity 1Neoplasms 1Neoplasm, Residual 1Myelodysplastic Syndromes 1Metastatic Solid Tumors 1Metabolic Syndrome 1Melanoma 1Lymphoproliferative Disorders 1Lymphomatoid Granulomatosis 1Lymphoma, T-Cell, Peripheral 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Lung Neoplasms 1Leukemia, Hairy Cell 1Hodgkin Disease 1Hematologic Neoplasms 1Heart Failure 1Epstein-Barr Virus Infections 1

Interventions

dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Hypnosis 1Hematologic Tests 1Educational Status 1Echocardiography 1Dexamethasone 1Calcium Dobesilate 1Acupressure 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dyspnea × Echocardiography × 1 year × Clear all
NCT04827563 2026-03-04

Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib

University of Chicago

Terminated
50 enrolled
OtherPlasma cell

Dyspnea, Multiple Myeloma, Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡